AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06362655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
Study NCT06561828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Description: Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).
Study NCT06779448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the objective and subjective stress parameters caused by the application of cotton rolls during treatments in the patient and dentist
Description: Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
Study NCT06779435 — intervention group
Intervention type: DRUG
Intervention: Low intensity treatment options
Description: Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks
Study NCT06779435 — intervention group
Intervention type: DRUG
Intervention: Conventional immunochemotherapy regimen
Description: Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks
Study NCT06779552 — intervention group
Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: PA Pressure Sensor
Study NCT06275919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 40 MG Oral Tablet
Description: REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Study NCT06561828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (iTBS)
Description: Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).
Study NCT06561828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham Theta Burst Stimulation (sham TBS)
Description: iTBS or cTBS delivered with placebo side of A/P coil.
Study NCT04653129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: * The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin.
Study NCT04653129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Nerve Repair
Description: Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
Study NCT05514717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-2056
Description: XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
Study NCT06406465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status
Study NCT06406465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 IV over 60 minutes on day 2
Study NCT04653129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Nerve Repair
Description: Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
Study NCT06406465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
Study NCT05236660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made shoes: pressure-optimized
Description: Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
Study NCT05236660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made indoor shoes: pressure optimized
Description: Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
Study NCT05236660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot temperature monitoring
Description: Personalised at-home daily foot temperature monitoring at high-risk regions.
Study NCT05236660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
Study NCT06275919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Standard of Care
Description: In this setting there are not drugs with indication. Every site will treat patients as per their experience.
Study NCT06414226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill and Fish Oil vs. Placebo
Description: Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
Study NCT06414226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Krill and Fish Oil vs. Placebo
Description: Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
Study NCT06524453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair accessible exercise program
Description: 1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes
Study NCT06459817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BB-02 therapy
Description: Biophysical stimulation with magnetic fields
Study NCT05373004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
Study NCT05373004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril Maleate 20 mg
Description: It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
Study NCT04836897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrizValve® valve and transapical delivery system
Description: Transcatheter aortic valve replacement system
Study NCT06779058 — intervention group
Intervention type: DEVICE
Intervention: MRE
Description: All imaging studies were performed by using a 1.5T/3.0-T MRI system
Study NCT06779058 — intervention group
Intervention type: DEVICE
Intervention: Liver biopsy
Description: Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.
Study NCT06777576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free exoskeleton
Description: A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces.
Study NCT06779097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vunakizumab (IL-17A inhibitor)
Description: Vunakizumab (IL-17A inhibitor)
Study NCT06778460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine-lidocaine group
Description: In the esketamine-lidocaine group, patients received esketamine (0.25 mg/kg) and lidocaine (1.5 mg/kg) at the induction of anesthesia, followed by the continuous infusion of esketamine (0.02 mg/kg∙h) and lidocaine (1.5 mg/kg∙h) until the end of surgery. Postoperatively, the patients received two pumps. One pump delivered a fixed-rate infusion of lidocaine at 1.0 mg.kg-1.h-1 and esketamine at 0.02 mg.kg-1.h-1 infusion for 72 hours. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Study NCT06778460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: In the conventional analgesia group, patients received the same volume of normal saline instead of lidocaine and esketamine until the end of surgery. Postoperatively, the paitents received two pumps. One pump was the same volume of normal saline instead of lidocaine and esketamine. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Study NCT06079216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer Led Making Connections Thru Music
Description: Volunteer led Group music therapy-based intervention
Study NCT06079216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staff Led Making Connections Thru Music
Description: Staff led Group music therapy-based intervention
Study NCT05230550 — intervention group
Intervention type: DRUG
Intervention: Somapacitan
Description: Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
Study NCT05873699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13-C-pyruvate
Description: Given by Injection
Study NCT06148818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive neck motor control exercise therapy
Description: The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
Study NCT06148818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
Study NCT06148818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
Study NCT05610826 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cytoreductive surgery
Description: Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
Study NCT05701085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
Study NCT05916170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Warnings
Description: Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
Study NCT05916170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Warnings
Description: No warnings posted in the hookah café
Study NCT05725161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
Study NCT05725161 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list control group with psychoeducation materials provided
Description: The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
Study NCT05653336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal® Closure Device System
Description: Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
Study NCT04733040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: MOR202 will be administered as an intravenous infusion
Study NCT05150795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Study NCT05150795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 100 micrograms ampoule
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Study NCT06293755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle patch
Description: with 20 units botulinum toxin
Study NCT06293755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal injection
Description: with 20 units botulinum toxin
Study NCT04299464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo for approximately 12 weeks.
Study NCT04299464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: Participants will receive oral RO7017773 for approximately 12 weeks.
Study NCT06481904 — intervention group
Intervention type: DRUG
Intervention: TZIELD (teplizumab-mzwv)
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study NCT06558604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg/40mL
Study NCT06558604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: 10mg/mL
Study NCT06558604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Product
Description: 10mg, 50mg and 100mg tablets
Study NCT06558604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Capsule
Description: 80mg capsules
Study NCT06378151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLT training
Description: Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed.
Study NCT05132075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: JDQ443 tablets, orally administered
Study NCT05132075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel concentrated solution for infusion, intravenously administered
Study NCT04815213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded autologous bone marrow derived MSC Intravaginally
Description: Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
Study NCT05610826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
Study NCT05610826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)
Description: PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood.
Study NCT05610826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Description: PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
Study NCT05764005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based tool (MAP- Management of Active surveillance in Prostate Cancer)
Description: A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
Study NCT05764005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MUSIC website
Description: Standard of care educational materials {add more detail}